Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • FDA moves to speed...

    FDA moves to speed nicotine replacement product development

    Written by Ruby Khatun Khatun Published On 2017-11-30T10:15:51+05:30  |  Updated On 18 Aug 2021 3:20 PM IST

    The U.S. Food and Drug Administration (FDA) said on Wednesday it is considering measures to speed development of products that help people quit smoking, including easing requirements for approval of over-the-counter nicotine replacement therapies.


    The agency said it is "re-evaluating and modernizing" its approach to regulating nicotine replacement therapies (NRT), which are typically sold as gums, patches, and lozenges. Because their effectiveness is limited, the FDA wants to give consumers a wider range of options.



    The new measures could enable e-cigarette companies to get the devices approved as medical products, which could offer consumers greater reassurance that they perform as advertised and also open the possibility of being covered by health insurance.

    FDA Commissioner Scott Gottlieb said in an interview that the announcement "is a big deal because we haven't talked a lot about what we can do to create additional pathways to bring additional nicotine replacement therapies to the market."


    Matthew Myers, president of the Campaign for Tobacco-Free Kids, welcomed the initiative.


    "Very few NRT products have been cleared in the last decade and very little change has been made to enhance the effectiveness of current NRTs," he said. "Sending a message that the FDA intends to be open to innovation and that it wants to talk about how to foster that innovation is different from where things have been."


    The announcement is part of a broad nicotine policy outlined by Gottlieb in July aimed at reducing disease and death from traditional cigarettes in part by transitioning smokers over to less harmful nicotine products including e-cigarettes.


    Existing NRTs were approved based on studies showing they helped people completely quit smoking for a specific period of time. Gottlieb said there are multiple alternative claims that a company could make that would be easier to prove.


    These could include the ability of the product to reduce cravings, help maintain abstinence from cigarettes or address speed of delivery of the nicotine.


    Steering a drug through a standard clinical trial process can be expensive and daunting. Gottlieb said he would welcome the opportunity to have discussions with e-cigarette companies about submitting products through the new drug pathway.


    "The whole idea here is to better define the policy of demonstrating safety and efficacy of NRTs," he said.


    The FDA has scheduled a public hearing on Jan. 26th




    (Reporting by Toni Clarke in Washington; Editing by Cynthia Osterman)



    e-cigarette companiesFDAgumslozengesmedical productsmovesnicotinenicotine replacement therapiesover-the-counterpatchesproduct developmentquitreplacementScott GottliebsmokingspeedU.S. Food and Drug Administration
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok